EKTAY
Elekta AB (publ) [EKTAY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
EKTAY Stock Summary
Top 10 Correlated ETFs
EKTAY
Top 10 Correlated Stocks
EKTAY
In the News
Is Elekta (EKTAY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Elekta (EKTAY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Elekta (EKTAY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Elekta (EKTAY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Elekta (EKTAY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Elekta AB (EKTAF) Q2 2024 Earnings Call Transcript
Elekta AB (OTCPK:EKTAF) Q2 2024 Earnings Conference Call November 30, 2023 4:00 AM ET Company Participants Cecilia Ketels - Head, IR Gustaf Salford - President & CEO Tobias Hagglov - CFO Conference Call Participants Mattias Vadsten - SEB Oliver Reinberg - Kepler Cheuvreux Kristofer Liljeberg - Carnegie Hassan Al-Wakeel - Barclays Rickard Anderkrans - Handelsbanken Lisa Clive - Bernstein Veronika Dubajova - Citi Robert Davies - Morgan Stanley Cecilia Ketels Good morning, everyone, and warm welcome to the presentation of Elekta's Second Quarter 2023-'24. My name is Cecilia Ketels, and I'm Head of Investor Relations at Elekta.
Elekta AB (publ) (EKTAF) Q3 2023 Earnings Call Transcript
Elekta AB (publ) (OTCPK:EKTAF) Q3 2023 Earnings Conference Call February 24, 2023 4:00 AM ET Company Participants Cecilia Ketels - Head of Investor Relations Gustaf Salford - President & Chief Executive Officer Tobias Hagglov - Chief Financial Officer Conference Call Participants Mattias Vadsten - SEB Erik Cassel - ABG Oliver Reinberg - Kepler Cheuvreux Rickard Anderkrans - Handelsbanken Julien Ouaddour - Bank of America David Adlington - JPMorgan Robert Davies - Morgan Stanley Cecilia Ketels Good morning, everyone, and warm welcome to the presentation of Elekta's Third Quarter 2022-2023. My name is Cecilia Ketels, and I'm Head of Investor Relations at Elekta.
Elekta AB (publ) (EKTAF) Q2 2023 Earnings Call Transcript
Elekta AB (publ) (OTCPK:EKTAF) Q2 2023 Results Conference Call November 24, 2022 12:00 PM ET Company Participants Cecilia Ketels - Head of IR Gustaf Salford - President & CEO Tobias Hagglov - CFO Conference Call Participants Erik Cassel - ABG Sundal Collier Mattias Vadsten - SEB Kristofer Liljeberg - Carnegie Robert Davies - Morgan Stanley Victor Forssell - Nordea Julien Ouaddour - Bank of America Oliver Reinberg - Kepler Cheuvreux Rickard Anderkrans - Handelsbanken David Adlington - JPMorgan Veronika Dubajova - Citi Cecilia Ketels Good morning, everyone, and warm welcome to the presentation of Elekta's Second Quarter 2022-23. My name is Cecilia Ketels, and I'm the Head of Investor Relations at Elekta.
Elekta AB (publ) (EKTAF) Q1 2023 Earnings Call Transcript
Elekta AB (publ) (OTCPK:EKTAF) Q1 2023 Earnings Conference Call August 25, 2022 4:00 AM ET Company Participants Cecilia Ketels - Head of IR Gustaf Salford - President & CEO Tobias Hagglov - CFO Conference Call Participants Erik Cassel - ABG Sundal Collier Kristofer Liljeberg - Carnegie Victor Forssell - Nordea Veronika Dubajova - Citi Rickard Anderkrans - Handelsbanken David Adlington - JPMorgan Cecilia Ketels Good morning, everyone, and warm welcome to the presentation of Elekta's First Quarter 2022/'23. My name is Cecilia Ketels, and I'm Head of Investor Relations at Elekta.
Elekta AB (publ)'s (EKTAF) CEO Gustaf Salford on Q4 2022 Results - Earnings Call Transcript
Elekta AB (publ) (OTCPK:EKTAF) Q4 2022 Earnings Conference Call May 25, 2022 4:00 AM ET Company Participants Cecilia Ketels - Head of Investor Relations Gustaf Salford - President and Chief Executive Officer Tobias Hagglov - Chief Financial Officer Conference Call Participants Patrick Wood - Bank of America Erik Cassel - ABG Sundal Collier Kristofer Liljeberg - Carnegie Rickard Anderkrans - Handelsbanken Victor Forssell - Nordea David Adlington - JPMorgan Oliver Reinberg - Kepler Cheuvreux Cecilia Ketels Good morning, everyone, and warm welcome to the presentation of Elekta's Fourth Quarter and our Fiscal Year 2021-2022. My name is Cecilia Ketels, and I'm Head of Investor Relations at Elekta.
EKTAY Financial details
EKTAY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-04-30
| Metric | History | 2019-04-30 | 2020-04-30 | 2021-04-30 | 2022-04-30 | 2023-04-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 35.48 | 38.21 | 36.02 | 38.08 | 44.15 | |
| Net income per share | 3.14 | 2.84 | 3.28 | 3.02 | 2.47 | |
| Operating cash flow per share | 4.24 | 2.65 | 6.68 | 4.86 | 5.14 | |
| Free cash flow per share | 2.52 | 0.66 | 4.46 | 1.18 | 1.05 | |
| Cash per share | 10.76 | 16.91 | 11.52 | 8.03 | 8.56 | |
| Book value per share | 20.36 | 21.23 | 21.45 | 23.32 | 25.46 | |
| Tangible book value per share | -3.98 | -3.55 | -1.53 | -3.53 | -5.21 | |
| Share holders equity per share | 20.36 | 21.23 | 21.45 | 23.32 | 25.46 | |
| Interest debt per share | 12.34 | 25.05 | 16.94 | 15.29 | 18.04 | |
| Market cap | 43.05B | 33.89B | 42.78B | 25.38B | 32.84B | |
| Enterprise value | 43.55B | 36.85B | 44.62B | 28.01B | 36.24B | |
| P/E ratio | 35.94 | 31.26 | 34.12 | 22 | 34.82 | |
| Price to sales ratio | 3.18 | 2.32 | 3.11 | 1.74 | 1.95 | |
| POCF ratio | 26.56 | 33.42 | 16.77 | 13.66 | 16.72 | |
| PFCF ratio | 44.75 | 134.47 | 25.08 | 56.41 | 82.1 | |
| P/B Ratio | 5.54 | 4.18 | 5.22 | 2.85 | 3.38 | |
| PTB ratio | 5.54 | 4.18 | 5.22 | 2.85 | 3.38 | |
| EV to sales | 3.21 | 2.52 | 3.24 | 1.93 | 2.15 | |
| Enterprise value over EBITDA | 16.22 | 12.52 | 14.55 | 10.42 | 14.58 | |
| EV to operating cash flow | 26.86 | 36.34 | 17.49 | 15.07 | 18.45 | |
| EV to free cash flow | 45.27 | 146.21 | 26.15 | 62.24 | 90.59 | |
| Earnings yield | 0.03 | 0.03 | 0.03 | 0.05 | 0.03 | |
| Free cash flow yield | 0.02 | 0.01 | 0.04 | 0.02 | 0.01 | |
| Debt to equity | 0.59 | 1.15 | 0.76 | 0.64 | 0.69 | |
| Debt to assets | 0.19 | 0.33 | 0.25 | 0.22 | 0.23 | |
| Net debt to EBITDA | 0.18 | 1.01 | 0.6 | 0.98 | 1.37 | |
| Current ratio | 1.08 | 1.38 | 1.11 | 1.11 | 1.13 | |
| Interest coverage | 10.87 | 7.74 | 8.18 | 11.1 | 6.33 | |
| Income quality | 1.03 | 0.7 | 1.57 | 1.24 | 1.64 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | |
| Payout ratio | 0.45 | 0.63 | 0.55 | 0.73 | 0.97 | |
| Sales general and administrative to revenue | 0.08 | 0.07 | 0.08 | 0.08 | 0.08 | |
| Research and developement to revenue | 0.12 | 0.11 | 0.11 | 0.09 | 0.08 | |
| Intangibles to total assets | 0.39 | 0.33 | 0.35 | 0.39 | 0.4 | |
| Capex to operating cash flow | -0.41 | -0.75 | -0.33 | -0.76 | -0.8 | |
| Capex to revenue | -0.05 | -0.05 | -0.06 | -0.1 | -0.09 | |
| Capex to depreciation | -0.7 | -0.6 | -0.7 | -1.36 | -1.47 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 37.9 | 36.81 | 39.8 | 39.81 | 37.6 | |
| ROIC | 0.1 | 0.07 | 0.09 | 0.08 | 0.07 | |
| Return on tangible assets | 0.08 | 0.06 | 0.08 | 0.07 | 0.05 | |
| Graham Net | -16.35 | -21.63 | -16.19 | -19.88 | -25.63 | |
| Working capital | 1000M | 4.27B | 1.31B | 1.32B | 1.67B | |
| Tangible asset value | -1.52B | -1.36B | -584M | -1.35B | -1.99B | |
| Net current asset value | -3.39B | -4.73B | -3.4B | -4.51B | -5.5B | |
| Invested capital | 0.59 | 1.15 | 0.76 | 0.64 | 0.69 | |
| Average receivables | 3.08B | 5.87B | 6.08B | 6.92B | 7.16B | |
| Average payables | 1.28B | 1.23B | 1.02B | 1.18B | 1.58B | |
| Average inventory | 1.88B | 2.69B | 2.52B | 2.41B | 2.8B | |
| Days sales outstanding | 165.63 | 139.92 | 174 | 182.6 | 152.22 | |
| Days payables outstanding | 66.14 | 44.2 | 45.49 | 54.16 | 62.76 | |
| Days of inventory on hand | 122.08 | 118.5 | 102.21 | 101.44 | 106.52 | |
| Receivables turnover | 2.2 | 2.61 | 2.1 | 2 | 2.4 | |
| Payables turnover | 5.52 | 8.26 | 8.02 | 6.74 | 5.82 | |
| Inventory turnover | 2.99 | 3.08 | 3.57 | 3.6 | 3.43 | |
| ROE | 0.15 | 0.13 | 0.15 | 0.13 | 0.1 | |
| Capex per share | -1.73 | -1.99 | -2.21 | -3.69 | -4.09 |
Quarterly Fundamentals Overview
Last date of statement is 2024-01-31 for Q3
| Metric | History | 2023-01-31 | 2023-04-30 | 2023-07-31 | 2023-10-31 | 2024-01-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 11.35 | 13.41 | 10.02 | 12.38 | 11.87 | |
| Net income per share | 0.57 | 1.43 | 0.62 | 0.9 | 0.8 | |
| Operating cash flow per share | 0.59 | 5.21 | -1.44 | 1.63 | 2.81 | |
| Free cash flow per share | -0.43 | 4.12 | -2.35 | 0.55 | 1.65 | |
| Cash per share | 3.19 | 5.87 | -31.03 | 4.89 | 6.16 | |
| Book value per share | 25.19 | 25.46 | 26.73 | 27.12 | 26.82 | |
| Tangible book value per share | -4.88 | -5.21 | -5.84 | 27.14 | 26.83 | |
| Share holders equity per share | 25.19 | 25.46 | 26.73 | 27.12 | 26.82 | |
| Interest debt per share | 14.91 | 17.7 | 17.94 | 18.14 | 16.15 | |
| Market cap | 28.39B | 32.84B | 32.64B | 29.08B | 30.04B | |
| Enterprise value | 32.81B | 36.24B | 37.02B | 34.05B | 34.83B | |
| P/E ratio | 32.86 | 15.04 | 34.29 | 21.13 | 24.62 | |
| Price to sales ratio | 6.55 | 6.41 | 8.53 | 6.14 | 6.62 | |
| POCF ratio | 126.18 | 16.49 | -59.24 | 46.67 | 28.02 | |
| PFCF ratio | -173.11 | 20.88 | -36.39 | 137.8 | 47.53 | |
| P/B Ratio | 2.95 | 3.38 | 3.2 | 2.81 | 2.93 | |
| PTB ratio | 2.95 | 3.38 | 3.2 | 2.81 | 2.93 | |
| EV to sales | 7.57 | 7.07 | 9.67 | 7.2 | 7.68 | |
| Enterprise value over EBITDA | 44.76 | 51.77 | 51.2 | 39.74 | 43.86 | |
| EV to operating cash flow | 145.83 | 18.2 | -67.19 | 54.66 | 32.49 | |
| EV to free cash flow | -200.07 | 23.04 | -41.27 | 161.39 | 55.11 | |
| Earnings yield | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | -0.01 | 0.05 | -0.03 | 0.01 | 0.02 | |
| Debt to equity | 0.59 | 0.69 | 0.66 | 0.66 | 0.59 | |
| Debt to assets | 0.2 | 0.23 | 0.22 | 0.22 | 0.2 | |
| Net debt to EBITDA | 6.03 | 4.85 | 6.06 | 5.81 | 6.03 | |
| Current ratio | 1.04 | 1.13 | 1.12 | 1.07 | 1.09 | |
| Interest coverage | 5.71 | 8.25 | 3.85 | 6.33 | 6.85 | |
| Income quality | 0.82 | 2.89 | -1.81 | 1.41 | 3.5 | |
| Dividend Yield | 0 | 0.01 | 0 | 0.02 | 0 | |
| Payout ratio | 0 | 0.84 | 0 | 1.33 | 0 | |
| Sales general and administrative to revenue | 0.1 | 0.06 | 0.08 | 0.07 | 0.08 | |
| Research and developement to revenue | 0.08 | 0.06 | 0.1 | 0.07 | 0.08 | |
| Intangibles to total assets | 0.41 | 0.4 | 0.4 | 0.41 | 0.41 | |
| Capex to operating cash flow | -1.73 | -0.21 | 0.63 | -0.66 | -0.41 | |
| Capex to revenue | -0.09 | -0.08 | -0.09 | -0.09 | -0.1 | |
| Capex to depreciation | -1.41 | -1.61 | -1.23 | -1.5 | -2.8 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 17.9 | 28.61 | 19.36 | 23.44 | 21.95 | |
| ROIC | 0.02 | 0.04 | 0.02 | 0.02 | 0.03 | |
| Return on tangible assets | 0.01 | 0.03 | 0.01 | 0.02 | 0.02 | |
| Graham Net | -23.39 | -28.32 | -62.94 | -27.78 | -26.5 | |
| Working capital | 567M | 1.67B | 1.54B | 1.02B | 1.23B | |
| Tangible asset value | -1.86B | -1.99B | -2.23B | -2.72B | -2.36B | |
| Net current asset value | -5.1B | -5.5B | -5.78B | -6.43B | -6.28B | |
| Invested capital | 0.59 | 0.69 | 0.66 | 0.66 | 0.59 | |
| Average receivables | 8.23B | 7.86B | 7.88B | 8.94B | 8.73B | |
| Average payables | 1.43B | 1.6B | 1.75B | 1.71B | 1.61B | |
| Average inventory | 3.28B | 3.2B | 3.4B | 3.77B | 3.67B | |
| Days sales outstanding | 180.35 | 123.57 | 205.2 | 173.89 | 164.86 | |
| Days payables outstanding | 46.57 | 50.97 | 67.96 | 51 | 46.82 | |
| Days of inventory on hand | 111.81 | 86.51 | 150.08 | 112.79 | 110.79 | |
| Receivables turnover | 0.5 | 0.73 | 0.44 | 0.52 | 0.55 | |
| Payables turnover | 1.93 | 1.77 | 1.32 | 1.76 | 1.92 | |
| Inventory turnover | 0.8 | 1.04 | 0.6 | 0.8 | 0.81 | |
| ROE | 0.02 | 0.06 | 0.02 | 0.03 | 0.03 | |
| Capex per share | -1.02 | -1.09 | -0.91 | -1.08 | -1.15 |
EKTAY Frequently Asked Questions
What is Elekta AB (publ) stock symbol ?
Elekta AB (publ) is a SE stock and trading under the symbol EKTAY
What is Elekta AB (publ) stock quote today ?
Elekta AB (publ) stock price is $7.09 today.
Is Elekta AB (publ) stock public?
Yes, Elekta AB (publ) is a publicly traded company.
Company Profile
- Volume Average 6.5K
- Market Capitalization 2.68B
- Employee 4.58K
- CEO Mr. Gustaf Salford
- Headquarters Stockholm,SE
- IPO Date 2009-03-03
-
Website
https://www.elekta.com 
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
